In long-acting analgesia for laboratory mice and rats…
Unlike compounded buprenorphine…
- Ethiqa XR is manufactured to the highest standards at an FDA regulated facility
- You can be certain you’re getting consistent quality that helps assure the integrity of your research outcomes
- Ethiqa XR was specifically developed for use in mice and rats
- You can count on the convenience of 3-day analgesia with just 1 injection to relieve concerns about breakthrough pain
An ethical imperativeMany industry organizations, including ACLAM, AALAS, and ASLAP, have developed official position statements recognizing the need for reducing the discomfort of lab animals with effective pain management. Ethiqa XR is an example of our commitment to unique solutions that answer unmet needs in animal health.
Proven long-acting pain relief
- Clinically significant blood levels were observed up to 72 hours after 1 subcutaneous injection
- Efficacy was demonstrated in studies conducted at Johns Hopkins University
- FDA-compliant supply chain and manufacturing
- Pharmaceutical grade pure, sterile, endotoxin-free components
- Made in the USA (manufactured in Pennsylvania)
Animal welfare protection
- Assures more accurate dosing using smaller syringes and needles
- Ensures control by managing the risk of inadequate or insufficient analgesia
We’re committed to leading the industry with quality-driven therapeutics.
Important Safety Information
For Rats and Mice:
Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression.
Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans.